Seaside Therapeutics, Inc.: Clinical Trials

8 completed, 5 terminated, 1 suspended. 6 Phase 2, 4 Phase 3, 2 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	6	Completed 3, Terminated 2, Suspended 1
Phase 3	4	Completed 2, Terminated 2
Phase 1	2	Completed 1, Terminated 1

Follow Seaside Therapeutics, Inc.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders STX209 (arbaclofen) - Autism Spectrum Disorders	Phase 3	Terminated	Seaside Therapeutics, Inc.	165	2011-11-01	2013-07-31
An Open Label Extension Study in Subjects With Fragile X Syndrome arbaclofen - Fragile X Syndrome	Phase 3	Terminated	Seaside Therapeutics, Inc.	357	2011-11-01	2013-07-31
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome arbaclofen, Placebo - Fragile X Syndrome	Phase 3	Completed	Seaside Therapeutics, Inc.	172	2011-06-01	2013-07-31
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders Arbaclofen - Autism Spectrum Disorders	Phase 2	Completed	Seaside Therapeutics, Inc.	150	2011-05-01	2013-07-31
Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome arbaclofen, placebo - Fragile X Syndrome	Phase 3	Completed	Seaside Therapeutics, Inc.	125	2011-05-01	2013-07-31
A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome STX107 - Fragile X Syndrome	Phase 2	Suspended	Seaside Therapeutics, Inc.	16	2011-05-01	2012-12-20
TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers R-baclofen - Autism	Phase 1	Terminated	Gonzalez-Heydrich, Joseph, M.D.	6	2010-10-01	2015-08-21
An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders arbaclofen - Autism Spectrum Disorders	Phase 2	Terminated	Seaside Therapeutics, Inc.	32	2010-02-01	2012-12-20
An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome Arbaclofen - Fragile X Syndrome	Phase 2	Terminated	Seaside Therapeutics, Inc.	45	2009-11-01	2012-12-20
A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107 STX107 - Fragile X Syndrome	Phase 1	Completed	Seaside Therapeutics, Inc.	40	2009-09-01	2010-02-08
Biomarker and DNA Collection in Subjects Participating in Protocol 22003 STX209 - Fragile X Syndrome		Completed	Seaside Therapeutics, Inc.	32	2009-05-01	2013-07-31
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders Arbaclofen - Autism Spectrum Disorders	Phase 2	Completed	Seaside Therapeutics, Inc.	32	2009-02-01	2013-06-14
Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001 STX209 - Fragile X Syndrome		Completed	Seaside Therapeutics, Inc.		2009-01-01	2013-07-31
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome STX209, Placebo - Fragile X Syndrome	Phase 2	Completed	Seaside Therapeutics, Inc.	63	2008-11-01	2013-05-06

Conditions studied

Fragile X Syndrome (9)  ·  Autism Spectrum Disorder (5)  ·  Autistic Disorder (5)  ·  Asperger Syndrome (1)  ·  Mental Disorders (1)

Interventions

arbaclofen placarbil (9)

Countries

United States (14)

Top investigators

Bryan King, MD, PhD (4)  ·  Craig Erikson, MD (4)  ·  James McCracken, MD (4)  ·  Jeremy Veenstra-VanderWeele, MD (4)  ·  Lawrence Ginsberg, MD (4)  ·  Linmarie Sikich, MD (4)  ·  Paul Wang, M.D. (4)  ·  Raun Melmed, MD (4)  ·  Elizabeth Berry-Kravis, MD, PhD (2)  ·  Jonathan Picker, MBChB, PhD (2)  ·  Lawrence Scahill, PhD (2)  ·  Randi Hagerman, MD (2)  ·  Shivkumar Hatti, MD (2)  ·  Ted Brown, MD, PhD (2)  ·  Alvaro Pascual-Leone, M.D. Ph. D. (1)